Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis

MeSH terms

• Age Factors
• Antibodies, Monoclonal, Humanized / administration & dosage
• Antibodies, Monoclonal, Humanized / adverse effects
• Antibodies, Monoclonal, Humanized / pharmacokinetics*
• Antibodies, Monoclonal, Humanized / therapeutic use*
• Body Weight*
• Dermatologic Agents / administration & dosage
• Dermatologic Agents / adverse effects
• Dermatologic Agents / pharmacokinetics*
• Dermatologic Agents / therapeutic use*
• Dose-Response Relationship, Drug
• Humans
• Logistic Models
• Metabolic Clearance Rate
• Psoriasis / drug therapy*
• Risk Assessment
• Sex Factors